"The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Bexsero is the second vaccine approved"...
Typhoid fever is an infectious disease caused by S. typhi. Humans are the only natural host and reservoir for S. typhi; infections result from the consumption of food or water that has been contaminated by the excretions of an acute case or a carrier. S. typhi organisms efficiently invade the human intestinal mucosae ultimately leading to bacteremia; following a typical 10- to 14-day incubation period, a systemic illness occurs. The clinical presentation of typhoid fever exhibits a broad range of severity and can be debilitating. Classical cases have fever, myalgia, anorexia, abdominal discomfort and headaches; the fever increases step-wise over a period of days and then may remain at 102°F to 106°F over 10 to 14 days before decreasing in a step-wise manner. Skin lesions known as rose spots may be present. Constipation is common in older children and adults, while diarrhea may occur in younger children. Among the less common but most severe complications are intestinal perforation and hemorrhage, and death. The course is typically more severe without appropriate antimicrobial therapy. The case fatality rate was reported to be approximately 10% to 20% in the pre-antibiotic era.1,2,3 During the period of 1983 to 1991 in the US, the case fatality rate reported to the Centers for Disease Control and Prevention (CDC) was 0.2% (9/4010).4 Infection of the gallbladder can lead to the chronic carrier state.
Typhoid fever is still endemic in many countries of the world where it is predominantly a disease of school-age children and may be a major public health problem. Most cases of typhoid fever in the US are thought to be acquired during foreign travel. During the periods of 1975 to 1984 and 1983 to 1984, respectively, 62% and 70% of the cases of typhoid fever reported to the CDC were acquired during foreign travel; this compares to 33% of cases during 1967-1972.5
In 1992, 414 cases of typhoid fever were reported to the CDC. Of these 414 cases, 1 (0.2%) case occurred in an infant under one year of age; 77 (18.6%) cases occurred in persons one to nine years of age; 81 (19.6%) cases occurred in persons 10 to 19 years of age; 251 (60.6%) cases occurred in individuals ≥ 20 years of age; the age was not available for 4 (1%) cases. One death was reported in 1991. (4) Domestic surveillance could underestimate the risk of typhoid fever in travelers since the disease is unlikely to be reported for persons who received diagnosis and treatment overseas.6
Approximately 2% to 4% of acute typhoid fever cases develop into a chronic carrier state. The chronic carrier state occurs more frequently with advanced age, and among females than males.2,7 These non-symptomatic carriers are the natural reservoir for S. typhi and can serve to maintain the disease in its endemic state or to directly infect new individuals. Outbreaks of typhoid fever are often traced to food handlers who are asymptomatic carriers.8
Two formulations were utilized in studies of the Typhoid Vi Polysaccharide Vaccine. These included the liquid formulation which is identical to Typhim Vi vaccine and a lyophilized formulation.
The protective efficacy of each of these formulations of the Typhoid Vi Polysaccharide Vaccine was assessed independently in two trials conducted in areas where typhoid fever is endemic. A single intramuscular dose of 25 mcg was used in these efficacy studies. A randomized doubleblind controlled trial with Typhim Vi vaccine (liquid formulation) was conducted in five villages west of Katmandu, Nepal. There were 6,908 vaccinated subjects: 3,454 received Typhim Vi vaccine and 3,454 in the control group received a 23-valent pneumococcal polysaccharide vaccine. Of the 6,908 subjects, 6,439 subjects were in the target population of 5 to 44 years of age. In addition, 165 children ages 2 to 4 years and 304 adults over 44 years of age were included in the study. The overall protective efficacy of Typhim Vi vaccine was 74% (95% confidence interval (CI): 49% to 87%) for blood culture confirmed cases of typhoid fever during 20 months of post-vaccination follow-up.9,10,11
The protective efficacy of the Typhoid Vi Polysaccharide Vaccine, lyophilized formulation, was evaluated in a randomized double-blind controlled trial conducted in South Africa. There were 11,384 vaccinated children 5 to 15 years of age; 5,692 children received the Vi capsular polysaccharide vaccine and 5,692 in the control group received Meningococcal Polysaccharide (Groups A+C) Vaccine. The protective efficacy for the Vi capsular polysaccharide (lyophilized formulation) group for blood culture confirmed cases of typhoid fever was 55% (95% CI: 30% to 70%) overall during 3 years of post-vaccination follow-up, and was 61%, 52% and 50%, respectively, for years 1, 2, and 3. Vaccination was associated with an increase in anti-Vi antibodies as measured by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay. Antibody levels remained elevated at 6 and 12 months post-vaccination.11,12
Because of the low incidence of typhoid fever, efficacy studies were not feasible in a US population.
Controlled comparative efficacy studies of Typhim Vi vaccine and other types of typhoid vaccines have not been performed.
An increase in serum anti-capsular antibodies is thought to be the basis of protection provided by Typhim Vi vaccine. However, a specific correlation of post-vaccination antibody levels with subsequent protection is not available, and the level of Vi antibody that will provide protection has not been determined. Also, limitations exist for comparing immunogenicity results from subjects in endemic areas, where some subjects have baseline serological evidence of prior S. typhi exposure, to naive populations such as most American travelers.
In endemic regions (Nepal, South Africa, Indonesia) where trials were conducted, pre-vaccination geometric mean antibody levels suggest that infection with S. typhi had previously occurred in a large percentage of the vaccinees. In these populations, specific antibody levels increased fourfold or greater in 68% to 87.5% of older children and adult subjects following vaccination. For 43 persons 15 to 44 years of age in the Nepal pilot study, geometric mean specific antibody levels pre- and 3 weeks post-vaccination were, respectively, 0.38 and 3.68 mcg antibody/mL by RIA; 79% had a four-fold or greater rise in Vi antibody levels.9,12
Immunogenicity and safety trials were conducted in an adult US population. A single dose of Typhim Vi vaccine induced a four-fold or greater increase in antibody levels in 88% and 96% of this adult population for 2 studies, respectively, following vaccination (see Table 1).10,13
Table 110,13: Vi ANTIBODY LEVELS IN US
ADULTS 18 TO 40 YEARS OF AGE GIVEN TYPHIM Vi VACCINE
|N||GEOMETRIC MEAN ANTIBODY LEVELS (mcg antibody/mL by RIA)||% ≥ 4 FOLD INCREASE (95% CI)|
|Pre||Post (4 weeks)|
|Trial 1 (1 lot)||54||0.16
(0.13 to 0.21)
(2.59 to 4.03)
(52/54) (87% to 100%)
|Trial 2 (2 lots combined)||97||0.17
(0.14 to 0.21)
(2.26 to 3.62)
(85/97) (81% to 94%)
No studies of safety and immunogenicity have been conducted in US children. A double-blind randomized controlled trial evaluating the safety and immunogenicity of Typhim Vi vaccine was performed in 175 Indonesian children. The percentage of 2- to 5-year-old children achieving a four-fold or greater increase in antibody levels at 4 weeks post-vaccination was 96.3% (52/54) (95% CI: 87.3% to 99.6%), and in the study subset of 2-year-old children was 94.4% (17/18) (95% CI: 72.7% to 99.9%). The geometric mean antibody levels (mcg antibody/mL by RIA) for the 2-to 5-year-old children and the subset of 2-year-olds were, respectively, 5.81 (4.36 to 7.77) and 5.76 (3.48 to 9.53).10,11
In the US Reimmunization Study, adults previously immunized with Typhim Vi vaccine in other studies were reimmunized with a 25 mcg dose at 27 or 34 months after the primary dose. Data on antibody response to primary immunization, decline following primary immunization, and response to reimmunization are presented in Table 2. Antibody levels attained following reimmunization at 27 or 34 months after the primary dose were similar to levels attained following the primary immunization.10,13 This response is typical for a T-cell independent polysaccharide vaccine in that reimmunization does not elicit higher antibody levels than primary immunization. The safety of reimmunization was also evaluated in this study (see ADVERSE REACTIONS section).
Table 210,13: US STUDIES IN 18- TO
40-YEAR-OLD ADULTS: KINETICS AND PERSISTSENCE OF Vi ANTIBODY* RESPONSE TO
PRIMARY IMMUNIZATION WITH TYPHIM Vi VACCINE, AND RESPONSE TO REIMMUNIZATION AT
27 OR 34 MONTHS
|PREDOSE 1||1 MONTH||11 MONTHS||18 MONTHS||27 MONTHS||34 MONTHS||1 MONTH POST REIMMUNIZATION¶|
|Level* 95% CI||0.19
|Level 95% CI||0.14
|* mcg antibody/mL by RIA
† Group 1: Reimmunized at 27 months following primary immunization.
‡ Group 2: Reimmunized at 34 months following primary immunization.
§ Not Done.
|| Antibody levels pre-reimmunization.
¶ Includes available data from all reimmunized subjects (subjects initially randomized to Typhim Vi vaccine, and subjects initially randomized to placebo who received open label Typhim Vi vaccine two weeks later).
Concurrently Administered Vaccines
Concomitant Administration of Typhim Vi and Menactra vaccine
In a double-blind, randomized, controlled clinical trial, 945 participants aged 18 through 55 years received Typhim Vi and Menactra vaccines concomitantly (N=469), or Typhim Vi vaccine followed one month later by Menactra vaccine (N=476). Sera were obtained approximately 28 days after each respective vaccination. The antibody response to Typhim Vi vaccine and to Menactra vaccine components were similar between groups.
1 Levine MM, et al. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47: 510-550, 1983
2 Levine MM. Typhoid Fever Vaccines. p 333-361. In Vaccines, Plotkin SA, Mortimer EA, eds. W.B. Saunders, 1988
3 Levine MM, et al. Typhoid Fever Chapter 5, In: Vaccines and Immunotherapy. Stanley J. Cryz, Jr., Editor. pp 59-72, 1991
4 CDC. Summary of Notifiable Diseases, United States 1992. MMWR 41: No. 55, 1993
5 Ryan CA, et al. Salmonella typhi infections in the United States, 1975-1984: Increasing Role of Foreign Travel. Rev Infect Dis 11:1-8, 1989
6 Woodruff BA, et al. A new look at typhoid vaccination. Information for the practicing physician. JAMA 265: 756-759, 1991
7 Ames WR, et al. Age and sex as factors in the development of the typhoid carrier state, and a method for estimating carrier prevalence. Am J Public Health 33: 221-230, 1943
8 CDC. Typhoid fever - Skagit County, Washington. MMWR 39: 749-751, 1990
9 Acharya IL, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med 317: 1101-1104, 1987
10 Unpublished data available from Sanofi Pasteur Inc., compiled 1991
11 Unpublished data available from Sanofi Pasteur SA
12 Klugman KP, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. The Lancet, 1165-1169, 1987
13 Keitel WA, et al. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccines 12: 195-199, 1994
Last reviewed on RxList: 10/10/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Typhim Information
Report Problems to the Food and Drug Administration
Find out what women really need.